BACKGROUND: Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML) patients. The aim of this study was to develop a disease-specific HRQOL questionnaire for patients with CML to supplement the European Organization for Research and Treatment of Cancer (EORTC)-QLQ C30. PATIENTS AND METHODS: The process followed a predefined and systematic stepwise iterative process as defined by the EORTC guidelines for questionnaire development. The process was divided into 3 phases: (1) generation of relevant HRQOL issues, (2) operationalization of the HRQOL issues into a set of items, and (3) pretesting the questionnaire for relevance and acceptability. Descriptive statistics and psychometric analyses were also performed. RESULTS: Overall, 655 CML patients were enrolled in 10 countries including the USA and countries in Europe and Asia. Interviews with health-care professionals experienced in CML (n = 59) were also conducted. Results from the interviews, clinical experiences, and statistical analyses were used to develop the EORTC QLQ-CML24. The final module consists of 24 items assessing the following aspects: symptom burden, impact on daily life and on worry/mood, body image problems, and satisfaction with care and with social life. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.73 to 0.83 for the proposed scales. CONCLUSION: The EORTC QLQ-CML24 is an internationally developed HRQOL questionnaire for CML patients, and its implementation in clinical research and practice can provide important information to facilitate clinical decision-making.
BACKGROUND: Health-related quality of life (HRQOL) is a key aspect for chronic myeloid leukemia (CML) patients. The aim of this study was to develop a disease-specific HRQOL questionnaire for patients with CML to supplement the European Organization for Research and Treatment of Cancer (EORTC)-QLQ C30. PATIENTS AND METHODS: The process followed a predefined and systematic stepwise iterative process as defined by the EORTC guidelines for questionnaire development. The process was divided into 3 phases: (1) generation of relevant HRQOL issues, (2) operationalization of the HRQOL issues into a set of items, and (3) pretesting the questionnaire for relevance and acceptability. Descriptive statistics and psychometric analyses were also performed. RESULTS: Overall, 655 CMLpatients were enrolled in 10 countries including the USA and countries in Europe and Asia. Interviews with health-care professionals experienced in CML (n = 59) were also conducted. Results from the interviews, clinical experiences, and statistical analyses were used to develop the EORTC QLQ-CML24. The final module consists of 24 items assessing the following aspects: symptom burden, impact on daily life and on worry/mood, body image problems, and satisfaction with care and with social life. Internal consistency, assessed with Cronbach's alpha coefficients, ranged from 0.73 to 0.83 for the proposed scales. CONCLUSION: The EORTC QLQ-CML24 is an internationally developed HRQOL questionnaire for CMLpatients, and its implementation in clinical research and practice can provide important information to facilitate clinical decision-making.
Authors: Hagop M Kantarjian; Neil P Shah; Jorge E Cortes; Michele Baccarani; Mohan B Agarwal; María Soledad Undurraga; Jianxiang Wang; Juan Julio Kassack Ipiña; Dong-Wook Kim; Michinori Ogura; Carolina Pavlovsky; Christian Junghanss; Jorge H Milone; Franck E Nicolini; Tadeusz Robak; Jan Van Droogenbroeck; Edo Vellenga; M Brigid Bradley-Garelik; Chao Zhu; Andreas Hochhaus Journal: Blood Date: 2011-12-09 Impact factor: 22.113
Authors: Loretta A Williams; Araceli G Garcia Gonzalez; Patricia Ault; Tito R Mendoza; Mary L Sailors; Janet L Williams; Furong Huang; Aziz Nazha; Hagop M Kantarjian; Charles S Cleeland; Jorge E Cortes Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: David Cella; Sally E Jensen; Kimberly Webster; Du Hongyan; Jin-Shei Lai; Steven Rosen; Martin S Tallman; Susan Yount Journal: Value Health Date: 2012-12 Impact factor: 5.725
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Elizabeth A Hahn; G Alastair Glendenning; Mark V Sorensen; Stacie A Hudgens; Brian J Druker; Francois Guilhot; Richard A Larson; Stephen G O'Brien; Deborah G Dobrez; Martee L Hensley; David Cella Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Loretta A Williams; Araceli Garcia-Gonzalez; Tito R Mendoza; Shireen Haq; Charles S Cleeland Journal: Support Care Cancer Date: 2018-08-10 Impact factor: 3.603
Authors: Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Rocco Crescenzo; Carla Mamolo; Arlene Reisman; Andreas Hochhaus; Tim H Brümmendorf Journal: J Cancer Res Clin Oncol Date: 2019-04-15 Impact factor: 4.553